July 24, 2017 05:47 PM EDT

Novavax makes a case for a do-over on its failed RSV vaccine — but it's an uphill climb

Ten months after Novavax shares $NVAX were routed by the failure of its RSV F vaccine in Phase III in older subjects, the biotech …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

No­vavax makes a case for a do-over on its failed RSV vac­cine — but it's an up­hill climb